Entering text into the input field will update the search result below

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript

May 06, 2021 12:00 AM ETSarepta Therapeutics, Inc. (SRPT)1 Comment
SA Transcripts profile picture
SA Transcripts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2021 Earnings Conference Call May 5, 2021 5:30 PM ET

Company Participants

Mary Jenkins - IR

Douglas Ingram - President, CEO & Director

Ian Estepan - EVP & CFO

Dallan Murray - SVP & Chief Commercial Officer

Gilmore O'Neill - EVP, R&D and Chief Medical Officer

Louise Rodino-Klapac - EVP & Chief Scientific Officer

Conference Call Participants

Tazeen Ahmad - Bank of America Merrill Lynch

Gil Blum - Needham & Company

Colin Bristow - UBS

Daniil Gataulin - Raymond James & Associates

Sonya Bhatia - Goldman Sachs Group

Timothy Lugo - William Blair & Company

Tessa Romero - JPMorgan Chase & Co.


Good afternoon, ladies and gentlemen, and welcome to the Sarepta Therapeutics First Quarter 2021 Earnings Call. [Operator Instructions].

I'd now like to introduce your host for today's program, Mary Jenkins, Senior Management, Investor Relations. Please go ahead.

Mary Jenkins

Thank you, Jonathan, and thank you all for joining today's call. Earlier today, we released our financial results for the first quarter 2021. The press release is available on our website at sarepta.com, and our 10-Q was filed with the Securities and Exchange Commission earlier this afternoon.

Joining us on the call today are Doug Ingram, Ian Estepan, Dallan Murray, Dr. Gilmore O'Neill and Dr. Louise Rodino-Klapac. After our formal remarks, we'll open the call for Q&A.

I'd like to note that during this call, we will be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from these forward-looking statements and any such risks can materially and adversely affect the business, the results of operations and trading prices for Sarepta's common stock.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.